You just read:

Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute Radiation Syndrome

News provided by

Bolder BioTechnology, Inc.

Aug 02, 2017, 08:26 ET